A new study has shown that pramipexole (Mirapexin®/Sifrol®) can significantly reduce sleep disturbance, often the most troublesome symptom experienced by people with Restless Legs Syndrome (RLS). The important finding, presented at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago, U.S.A., highlights the benefit of an RLS treatment, which effectively targets the core symptoms of the condition, such as an uncontrollable urge to move the legs, as well as secondary symptoms, including sleep disturbance.